Neratinib received FDA approval on July 21, 2017 [1]. This approval was for the extended adjuvant treatment of adult patients with a history of early-stage HER2-positive breast cancer [1].
What is neratinib approved to treat?
Neratinib, marketed as Nerlynx, is approved for extended adjuvant treatment in patients who have previously undergone surgery and a defined course of adjuvant therapy for early-stage HER2-positive breast cancer [1]. This treatment aims to reduce the risk of invasive breast cancer recurrence [1].
When does neratinib's patent exclusivity expire?
Patent exclusivity for neratinib is determined by several factors, including listed patents and any potential patent challenges or extensions. DrugPatentWatch.com tracks these details, and specific expiration dates can be found on their platform. For example, the United States Patent and Trademark Office (USPTO) may grant patent term extensions based on regulatory review periods [2].
How does neratinib work?
Neratinib is a tyrosine kinase inhibitor that targets the HER2 and EGFR pathways [1]. By inhibiting these pathways, it blocks signaling that can drive the growth of HER2-positive cancer cells [1].
What are the risks associated with neratinib?
The most common side effects reported with neratinib include diarrhea, nausea, abdominal pain, fatigue, rash, stomatitis, and decreased appetite [1]. Severe diarrhea is a significant concern and can lead to dehydration and electrolyte imbalances [1]. Liver toxicity and exacerbation of pre-existing conditions are also potential risks [1].
What are the alternatives to neratinib for HER2-positive breast cancer?
For early-stage HER2-positive breast cancer, treatment typically involves surgery, chemotherapy, and HER2-targeted therapies like trastuzumab [3]. After initial treatment, extended adjuvant therapies may be considered, with neratinib being one option for select patients [1, 3]. Other HER2-targeted agents are also used in various stages of breast cancer treatment [3].
How is neratinib's approval monitored?
Following FDA approval, neratinib is subject to post-market surveillance. This includes monitoring for adverse events and ongoing clinical trials to further understand its long-term efficacy and safety profile [1].
Can biosimilars of neratinib be developed?
The development of biosimilars for small molecule drugs like neratinib is generally not applicable in the same way as for biologics. Biosimilars refer to highly similar versions of complex biological medicines. For small molecule drugs, the focus is on generic versions, which are chemically identical to the original drug and must demonstrate bioequivalence [4]. The availability of generic neratinib would depend on patent expirations and regulatory pathways for generic drug approval.
---
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration
3. National Cancer Institute
4. U.S. Food & Drug Administration